The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...
This opening segment establishes the clinical context for a 66 year old man with well differentiated, non functioning, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results